Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies

Wang, Qiang; Ju, Xiaoli; Wang, Jiayou; Fan, Yu; Ren, Meijia; Zhang, Heng

doi:10.1016/j.canlet.2018.08.028

Cited by 192 publications

(132 citation statements)

References 99 publications

Supporting

Mentioning

130

Contrasting

Order By: Relevance

“…Treatment related adverse events of any grade and grade 3-4 occurred in 64% and 13% of patients respectively. ORR is 18% (95% CI, [13][14][15][16][17][18][19][20][21][22][23][24] and does not depend much on prior treatment: 17% after platinum, 15% after cetuximab. Duration Of Response (DOR) is high with a not reached median (range, 2+ to 30+ months), 71% of responses lasted more than 12 months and five patients completed the study after 2 years of treatment with pembrolizumab.…”

Section: Keynote-012 Phase 1b Study: Anti-tumor Activity Of Pembrolizmentioning

confidence: 97%

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Borel

Jung

Burgy

2020

Cancers

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) in the recurrent or metastatic (R/M) setting is a devastating disease with a poor prognosis. Until recently, the reference first line treatment was the EXTREME protocol, which yields a 10.1 months median survival, and almost no effective treatment are available in second line. Immune checkpoint inhibitors (ICIs) have changed the prognosis of several metastatic solid tumors. Given their inflammatory profile and high mutational burden, HNSCC is a good candidate for ICIs treatments. First, a strong pembrolizumab efficacy signal was shown in the Keynote-012 Phase Ib study. Then, the phase III Checkmate-141 study validated the efficacy of nivolumab in platinum-resistant patients. Finally, the first line conquest is acquired since the final results of the keynote-048 phase III study that demonstrated the superiority of pembrolizumab versus EXTREME in CPS ≥ 1 patients, and with the addition of platinum and 5FU in all patients. However, the first line treatment landscape is not frozen. Two studies (Checkmate-651 and Kestrel) are investigating the efficacy of the combination of antibodies raised against CTLA-4 and PD-(L)1. Results are impatiently awaited. Further progress needs the use of new immunotherapeutic agents such as monalizumab or ICOS agonist rather in combination with an anti-PD(L)1. New associations of ICIs and chemotherapeutic or targeted therapeutic agents are also actively investigated. Finally, ICIs has to be studied in the locally advanced setting where there is a chance of cure. Several trials are testing the potential synergistic combination of ICIs with radiotherapy and platinum or cetuximab, or ICIs used in a neoadjuvant setting.

show abstract

Section: Keynote-012 Phase 1b Study: Anti-tumor Activity Of Pembrolizmentioning

confidence: 97%

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Borel

Jung

Burgy

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…In turn, chemotherapy is not solely used to induce tumor cell toxicity and death, and its strength results from the antitumor immune responses primed by immunogenic cell death (ICD). ICD is characterized by the up‐regulation of signaling expression in tumor cells, including the exposure of calreticulin, secretion of adenosine triphosphate, and release of high mobility group box 1 (Q. Wang et al, ; Y.‐J. Wang, Fletcher, Yu, & Zhang, ).…”

Section: Combinational Cancer Immunotherapy With Nanoparticlesmentioning

confidence: 99%

Nanotechnology platforms for cancer immunotherapy

Yang

Zhao

et al. 2019

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Various cancer therapies have advanced remarkably over the past decade. Unlike the direct therapeutic targeting of tumor cells, cancer immunotherapy is a new strategy that boosts the host's immune system to detect specific cancer cells for efficient elimination. Nanoparticles incorporating immunomodulatory agents can activate immune cells and modulate the tumor microenvironment to enhance antitumor immunity. Such nanoparticle‐based cancer immunotherapies have received considerable attention and have been extensively studied in recent years. This review thus focuses on nanoparticle‐based platforms (especially naturally derived nanoparticles and synthetic nanoparticles) utilized in recent advances; summarizes delivery systems that incorporate various immune‐modulating agents, including peptides and nucleic acids, immune checkpoint inhibitors, and other small immunostimulating agents; and introduces combinational cancer immunotherapy with nanoparticles, especially nanoparticle‐based photo‐immunotherapy and nanoparticle‐based chemo‐immunotherapy. Undoubtedly, the recent studies introduced in this review prove that nanoparticle‐incorporated cancer immunotherapy is a highly promising treatment modality for patients with cancer. Nonetheless further research is needed to solve safety concerns and improve efficacy of nanoplatform‐based cancer immunotherapy for future clinical application. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

“…1-9 A substantial number of subsequent studies have shed light on the intricate molecular and cellular mechanisms that underlie the ability of cancer cells to undergo (and the host immune system to detect) ICD. 8,[10][11][12][13][14][15][16][17][18][19][20][21] Based on a series of fundamental studies, preclinical validations and clinical biomarker assessments [22][23][24] ICD can be defined as a functionally unique RCD subtype that is sufficient for the elicitation of adaptive immunity specifically directed toward antigens derived from cell "corpses". 4, 9,12,15,21,[25][26][27][28][29][30][31][32][33][34][35][36] It is now well acknowledged that, upon antigenic priming coupled to the emission of damage-associated molecular patterns (DAMPs) and immunostimulatory cytokines, 8,9,12,15,[19][20][21][27][28][29]31,[36][37][38]...…”

Section: Introductionmentioning

confidence: 99%

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

et al. 2020

View full text Add to dashboard Cite

The term 'immunogenic cell death' (ICD) denotes an immunologically unique type of regulated cell death that enables, rather than suppresses, T cell-driven immune responses that are specific for antigens derived from the dying cells. The ability of ICD to elicit adaptive immunity heavily relies on the immunogenicity of dying cells, implying that such cells must encode and present antigens not covered by central tolerance (antigenicity), and deliver immunostimulatory molecules such as damage-associated molecular patterns and cytokines (adjuvanticity). Moreover, the host immune system must be equipped to detect the antigenicity and adjuvanticity of dying cells. As cancer (but not normal) cells express several antigens not covered by central tolerance, they can be driven into ICD by some therapeutic agents, including (but not limited to) chemotherapeutics of the anthracycline family, oxaliplatin and bortezomib, as well as radiation therapy. In this Trial Watch, we describe current trends in the preclinical and clinical development of ICD-eliciting chemotherapy as partner for immunotherapy, with a focus on trials assessing efficacy in the context of immunomonitoring.

show abstract

Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies

Cited by 192 publications

References 99 publications

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Nanotechnology platforms for cancer immunotherapy

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

Contact Info

Product

Resources

About